Ulcerative Colitis Resource Center

Ulcerative Colitis Resource Center

August 31, 2016
1 min read
Save

Janssen to provide free therapeutic drug monitoring for IBD patients on Remicade

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Janssen Biotech, Inc., has partnered with Miraca Life Sciences and its InformTx therapeutic drug monitoring service to develop the Janssen 2Inform program, which will provide two free therapeutic drug monitoring tests per year for patients with inflammatory bowel disease being treated with Remicade, according to a press release.

Accumulating evidence has shown serum anti-tumor necrosis factor drug and antidrug antibody concentrations are associated with clinical outcomes in IBD. Thus, therapeutic drug monitoring (TDM) is becoming more widely recognized as an important tool for maximizing drug efficacy, minimizing toxicity and maintaining remission.

“The treatment goal with IBD is to get symptoms under control and in remission as quickly as possible, but treating these diseases is not a one-size-fits-all approach as each patient responds differently to medication,” Andrew Greenspan, MD, vice president of medical affairs at Janssen Biotech, said in the press release. “Through Janssen 2Inform, TDM test results can help HCPs evaluate how a patient is responding to Remicade [infliximab, Janssen] and, in turn, identify steps to optimize the patient’s response.”

Through the program, TDM blood tests are drawn from a patient and sent overnight to be analyzed by Miraca Life Sciences, which will then report results electronically to the physician within 3 to 5 business days, according to the press release.

“We are committed to providing doctors with the tools they need to personalize a treatment plan for their patients living with IBD,” Jay Popp, MD, medical director at Janssen Biotech, said in the press release. “In our research, we found many doctors don’t use TDM because it isn’t covered by insurance, so Janssen is proud to launch Janssen 2Inform as a solution to this access barrier, and to help improve IBD patient care.”

Disclosures: Greenspan and Popp are employed by Janssen Biotech.

Editor’s Note:This article was updated on September 1 with clarifications from the article source.